![]() ![]() Majority of the cases were from the high-income and/or middle-income countries. The mean (SD) period between development of herpes zoster and COVID-19 vaccination was 7.64 (6.92) days. There were cases with known risk factors for herpes zoster, which included age more than 50 years (n = 36), immunological disorders (n = 10), chronic disease (n = 25), metabolic disorder (n = 13), malignancy (n = 4), and psychiatric disorder (n = 2). Individual case report references were filtered for any pertinent cases.Ī total of 54 cases consisting of 27 male and 27 female patients have been reported. ![]() We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like "Shingles," "Herpes zoster," "Varicella zoster," "COVID-19," "Vaccine," "SARS-CoV-2." No filters including country of publication, language, type of articles were applied. ![]() ![]() And to identify on whether COVID-19 vaccine has temporal relationship between development of herpes zoster (HZ). To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID-19 vaccines. Although the COVID-19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. ![]()
0 Comments
Leave a Reply. |